In CRC cells, the combination of Ru-1 and regorafenib dramatically reduced pAkt, PI3K, p-ERK, p38 MAP kinase, and total Akt, JNK, ERK, and VEGFA. This evidence concerns the gene AKT1 and colorectal carcinoma.